Clinical Trial Details
| Trial ID: | L3317 |
| Source ID: | NCT05897216 |
| Associated Drug: | Ckd-383 |
| Title: | Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029 |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes |
| Interventions: | DRUG: CKD-383|DRUG: CKD-501, D745, D150, D029 |
| Outcome Measures: | Primary: Cmax of CKD-383, Cmax: Maximum plasma concentration of the drug, Pre-does(0 hour), Post-dose(0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hour)|AUCt of CKD-383, AUCt: Area under the concentration-time curve from time zero to time, Pre-does(0 hour), Post-dose(0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 hour) | |
| Sponsor/Collaborators: | Sponsor: Chong Kun Dang Pharmaceutical |
| Gender: | ALL |
| Age: | ADULT |
| Phases: | PHASE1 |
| Enrollment: | 30 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2023-07-14 |
| Completion Date: | 2023-08-08 |
| Results First Posted: | |
| Last Update Posted: | 2024-01-23 |
| Locations: | CHA Bundang Medical Center, CHA University, Seongnam-si, Bundang, 13497, Korea, Republic of |
| URL: | https://clinicaltrials.gov/show/NCT05897216 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|